Glycan modification of glioblastoma‐derived extracellular vesicles enhances receptor‐mediated targeting of dendritic cells

Glioblastoma is the most prevalent and aggressive primary brain tumour for which total tumour lysate‐pulsed dendritic cell vaccination is currently under clinical evaluation. Glioblastoma extracellular vesicles (EVs) may represent an enriched cell‐free source of tumour‐associated (neo‐) antigens to pulse dendritic cells (DCs) for the initiation of an anti‐tumour immune response. Capture and uptake of EVs by DCs could occur in a receptor‐mediated...